The Nuclear Medicine Market is projected to grow from USD 10.42 billion in 2023 to USD 30.81 billion by 2032, at a compound annual growth rate (CAGR) of 12.8%. Key factors driving this growth include an increase in chronic diseases such as cancer and cardiovascular conditions, advancements in imaging modalities, and innovations in radiopharmaceuticals. Diagnostic products currently dominate the market due to the extensive use of SPECT and PET imaging, while therapeutic products, particularly those utilizing alpha and beta emitters for targeted cancer therapy, are expected to grow the fastest. North America is identified as the largest market for nuclear medicine, thanks to its advanced healthcare infrastructure, whereas the Asia-Pacific region is anticipated to experience the highest growth rates, supported by increased healthcare investments and government initiatives in countries like China, India, and Japan.
Thu, 05 Sep 2024 13:38:35 GMT | WhaTech